Cost-Effectiveness and Clinical Benefits of Germline BRCA Testing in Patients With TNBC and HR+/HER2− Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits
Br. J. Cancer 2022 Dec 23;[EPub Ahead of Print], HL Wu, ZY Luo, ZL He, Y Gong, M Mo, WK Ming, GY LiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.